| Hazard Information | Back Directory | [Description]
MTX-23 is an AR PROTAC. MTX-23 has been designed to simultaneously bind AR's DNA binding domain (DBD) and the Von Hippel-Lindau (VHL) E3 ubiquitin ligase. | [Uses]
MTX-23 is an AR-based PROTAC. MTX-23 inhibits CaP cellular proliferation by degrading AR-V7 and AR-FL. MTX-23 induces apoptosis[1]. | [in vivo]
MTX-23 (compound 16; 2.5 mg/mL; intratumor injection) inhibits tumor growth in nu/nu mice with 22Rvl-EnzR tumor xenografts[1]. | Animal Model: | nu/nu mice with 22Rvl-EnzR tumor xenografts[1] | | Dosage: | 2.5 mg/mL | | Administration: | intratumor injection | | Result: | Inhibited tumor growth in nu/nu mice with 22Rvl-EnzR tumor xenografts. |
| [References]
[1] Jenny D, et, al. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor. WO2021236695. |
|
|